efg ph20 sc
efg ph20 sc: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Lead developer: ARGENX SE (ARGX)
Development Pipeline (1)
| Company | Phase |
|---|---|
| ARGENX SE (ARGX) | Phase 4 |
Clinical Trials (1)
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy
Frequently asked questions
Who is developing efg ph20 sc?
efg ph20 sc is being developed by ARGENX SE.
How many clinical trials involve efg ph20 sc?
BioSniper tracks 1 clinical trial involving efg ph20 sc.
Analyze ARGENX SE & efg ph20 sc with AI
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company